A citation-based method for searching scientific literature

Marisa P McGinley, Carolyn H Goldschmidt, Alexander D Rae-Grant. JAMA 2021
Times Cited: 176







List of co-cited articles
528 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.
Alan J Thompson, Brenda L Banwell, Frederik Barkhof, William M Carroll, Timothy Coetzee, Giancarlo Comi, Jorge Correale, Franz Fazekas, Massimo Filippi, Mark S Freedman,[...]. Lancet Neurol 2018
25


Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition.
Clare Walton, Rachel King, Lindsay Rechtman, Wendy Kaye, Emmanuelle Leray, Ruth Ann Marrie, Neil Robertson, Nicholas La Rocca, Bernard Uitdehaag, Ingrid van der Mei,[...]. Mult Scler 2020
350
14

Multiple sclerosis - a review.
R Dobson, G Giovannoni. Eur J Neurol 2019
495
12

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.
Chris H Polman, Stephen C Reingold, Brenda Banwell, Michel Clanet, Jeffrey A Cohen, Massimo Filippi, Kazuo Fujihara, Eva Havrdova, Michael Hutchinson, Ludwig Kappos,[...]. Ann Neurol 2011
11

2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis.
Mike P Wattjes, Olga Ciccarelli, Daniel S Reich, Brenda Banwell, Nicola de Stefano, Christian Enzinger, Franz Fazekas, Massimo Filippi, Jette Frederiksen, Claudio Gasperini,[...]. Lancet Neurol 2021
110
10

Defining the clinical course of multiple sclerosis: the 2013 revisions.
Fred D Lublin, Stephen C Reingold, Jeffrey A Cohen, Gary R Cutter, Per Soelberg Sørensen, Alan J Thompson, Jerry S Wolinsky, Laura J Balcer, Brenda Banwell, Frederik Barkhof,[...]. Neurology 2014
10

Multiple sclerosis.
Alan J Thompson, Sergio E Baranzini, Jeroen Geurts, Bernhard Hemmer, Olga Ciccarelli. Lancet 2018
831
9

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Xavier Montalban, Stephen L Hauser, Ludwig Kappos, Douglas L Arnold, Amit Bar-Or, Giancarlo Comi, Jérôme de Seze, Gavin Giovannoni, Hans-Peter Hartung, Bernhard Hemmer,[...]. N Engl J Med 2017
916
9

Treatment of Multiple Sclerosis: A Review.
Stephen L Hauser, Bruce A C Cree. Am J Med 2020
162
8

Multiple sclerosis.
Massimo Filippi, Amit Bar-Or, Fredrik Piehl, Paolo Preziosa, Alessandra Solari, Sandra Vukusic, Maria A Rocca. Nat Rev Dis Primers 2018
474
7

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
Chris H Polman, Paul W O'Connor, Eva Havrdova, Michael Hutchinson, Ludwig Kappos, David H Miller, J Theodore Phillips, Fred D Lublin, Gavin Giovannoni, Andrzej Wajgt,[...]. N Engl J Med 2006
7

Immunopathology of multiple sclerosis.
Calliope A Dendrou, Lars Fugger, Manuel A Friese. Nat Rev Immunol 2015
7

Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.
Maria P Sormani, Nicola De Rossi, Irene Schiavetti, Luca Carmisciano, Cinzia Cordioli, Lucia Moiola, Marta Radaelli, Paolo Immovilli, Marco Capobianco, Maria Trojano,[...]. Ann Neurol 2021
255
6

Multiple Sclerosis.
Daniel S Reich, Claudia F Lucchinetti, Peter A Calabresi. N Engl J Med 2018
6

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Ludwig Kappos, Ernst-Wilhelm Radue, Paul O'Connor, Chris Polman, Reinhard Hohlfeld, Peter Calabresi, Krzysztof Selmaj, Catherine Agoropoulou, Malgorzata Leyk, Lixin Zhang-Auberson,[...]. N Engl J Med 2010
6

Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis.
Kjetil Bjornevik, Marianna Cortese, Brian C Healy, Jens Kuhle, Michael J Mina, Yumei Leng, Stephen J Elledge, David W Niebuhr, Ann I Scher, Kassandra L Munger,[...]. Science 2022
326
6

New diagnostic criteria for multiple sclerosis: guidelines for research protocols.
C M Poser, D W Paty, L Scheinberg, W I McDonald, F A Davis, G C Ebers, K P Johnson, W A Sibley, D H Silberberg, W W Tourtellotte. Ann Neurol 1983
5

Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies.
Anat Achiron, Mathilda Mandel, Sapir Dreyer-Alster, Gil Harari, David Magalashvili, Polina Sonis, Mark Dolev, Shay Menascu, Shlomo Flechter, Rina Falb,[...]. Ther Adv Neurol Disord 2021
217
5

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study.
Amit Bar-Or, Jonathan C Calkwood, Cathy Chognot, Joanna Evershed, Edward J Fox, Ann Herman, Marianna Manfrini, John McNamara, Derrick S Robertson, Daniela Stokmaier,[...]. Neurology 2020
200
5

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
Ludwig Kappos, Amit Bar-Or, Bruce A C Cree, Robert J Fox, Gavin Giovannoni, Ralf Gold, Patrick Vermersch, Douglas L Arnold, Sophie Arnould, Tatiana Scherz,[...]. Lancet 2018
457
5

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Stephen L Hauser, Amit Bar-Or, Giancarlo Comi, Gavin Giovannoni, Hans-Peter Hartung, Bernhard Hemmer, Fred Lublin, Xavier Montalban, Kottil W Rammohan, Krzysztof Selmaj,[...]. N Engl J Med 2017
885
5

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Jeffrey A Cohen, Frederik Barkhof, Giancarlo Comi, Hans-Peter Hartung, Bhupendra O Khatri, Xavier Montalban, Jean Pelletier, Ruggero Capra, Paolo Gallo, Guillermo Izquierdo,[...]. N Engl J Med 2010
5

The prevalence of MS in the United States: A population-based estimate using health claims data.
Mitchell T Wallin, William J Culpepper, Jonathan D Campbell, Lorene M Nelson, Annette Langer-Gould, Ruth Ann Marrie, Gary R Cutter, Wendy E Kaye, Laurie Wagner, Helen Tremlett,[...]. Neurology 2019
474
5

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Jeffrey A Cohen, Alasdair J Coles, Douglas L Arnold, Christian Confavreux, Edward J Fox, Hans-Peter Hartung, Eva Havrdova, Krzysztof W Selmaj, Howard L Weiner, Elizabeth Fisher,[...]. Lancet 2012
802
5

Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
Ludwig Kappos, Robert J Fox, Michel Burcklen, Mark S Freedman, Eva K Havrdová, Brian Hennessy, Reinhard Hohlfeld, Fred Lublin, Xavier Montalban, Carlo Pozzilli,[...]. JAMA Neurol 2021
57
8

Multiple Sclerosis: Mechanisms and Immunotherapy.
Clare Baecher-Allan, Belinda J Kaskow, Howard L Weiner. Neuron 2018
412
4

Microglia in Central Nervous System Inflammation and Multiple Sclerosis Pathology.
Sofie Voet, Marco Prinz, Geert van Loo. Trends Mol Med 2019
202
4

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.
Gustavo Luna, Peter Alping, Joachim Burman, Katharina Fink, Anna Fogdell-Hahn, Martin Gunnarsson, Jan Hillert, Annette Langer-Gould, Jan Lycke, Petra Nilsson,[...]. JAMA Neurol 2020
250
4

The 2013 clinical course descriptors for multiple sclerosis: A clarification.
Fred D Lublin, Timothy Coetzee, Jeffrey A Cohen, Ruth A Marrie, Alan J Thompson. Neurology 2020
49
8

Active induction of experimental allergic encephalomyelitis.
Ingunn M Stromnes, Joan M Goverman. Nat Protoc 2006
418
4

Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues.
Ralph H B Benedict, Maria Pia Amato, John DeLuca, Jeroen J G Geurts. Lancet Neurol 2020
133
4

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Gavin Giovannoni, Giancarlo Comi, Stuart Cook, Kottil Rammohan, Peter Rieckmann, Per Soelberg Sørensen, Patrick Vermersch, Peter Chang, Anthony Hamlett, Bruno Musch,[...]. N Engl J Med 2010
552
4

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Alasdair J Coles, Cary L Twyman, Douglas L Arnold, Jeffrey A Cohen, Christian Confavreux, Edward J Fox, Hans-Peter Hartung, Eva Havrdova, Krzysztof W Selmaj, Howard L Weiner,[...]. Lancet 2012
793
4

Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.
Roberta Magliozzi, Owain Howell, Abhilash Vora, Barbara Serafini, Richard Nicholas, Maria Puopolo, Richard Reynolds, Francesca Aloisi. Brain 2007
919
4

Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.
Ludwig Kappos, Jerry S Wolinsky, Gavin Giovannoni, Douglas L Arnold, Qing Wang, Corrado Bernasconi, Fabian Model, Harold Koendgen, Marianna Manfrini, Shibeshih Belachew,[...]. JAMA Neurol 2020
114
4

Teriflunomide and its mechanism of action in multiple sclerosis.
Amit Bar-Or, Andrew Pachner, Francoise Menguy-Vacheron, Johanne Kaplan, Heinz Wiendl. Drugs 2014
199
4


Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Peter A Calabresi, Ernst-Wilhelm Radue, Douglas Goodin, Douglas Jeffery, Kottil W Rammohan, Anthony T Reder, Timothy Vollmer, Mark A Agius, Ludwig Kappos, Tracy Stites,[...]. Lancet Neurol 2014
571
4

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
Ralf Gold, Ludwig Kappos, Douglas L Arnold, Amit Bar-Or, Gavin Giovannoni, Krzysztof Selmaj, Carlo Tornatore, Marianne T Sweetser, Minhua Yang, Sarah I Sheikh,[...]. N Engl J Med 2012
4

Multiple sclerosis: experimental models and reality.
Hans Lassmann, Monika Bradl. Acta Neuropathol 2017
282
3

Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque.
Josa M Frischer, Stephen D Weigand, Yong Guo, Nilufer Kale, Joseph E Parisi, Istvan Pirko, Jay Mandrekar, Stephan Bramow, Imke Metz, Wolfgang Brück,[...]. Ann Neurol 2015
353
3

Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: a retrospective autopsy cohort analysis.
Sabina Luchetti, Nina L Fransen, Corbert G van Eden, Valeria Ramaglia, Matthew Mason, Inge Huitinga. Acta Neuropathol 2018
152
3

Defining secondary progressive multiple sclerosis.
Johannes Lorscheider, Katherine Buzzard, Vilija Jokubaitis, Tim Spelman, Eva Havrdova, Dana Horakova, Maria Trojano, Guillermo Izquierdo, Marc Girard, Pierre Duquette,[...]. Brain 2016
199
3

Real-world adherence to, and persistence with, once- and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysis.
Jacqueline A Nicholas, Natalie C Edwards, Roger A Edwards, Anna Dellarole, Megan Grosso, Amy L Phillips. BMC Neurol 2020
22
13

Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis.
Joseph Menzin, Christina Caon, Christine Nichols, Leigh Ann White, Mark Friedman, Michael W Pill. J Manag Care Pharm 2013
151
3

The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis.
V Devonshire, Y Lapierre, R Macdonell, C Ramo-Tello, F Patti, P Fontoura, L Suchet, R Hyde, I Balla, E M Frohman,[...]. Eur J Neurol 2011
262
3

Measuring Adherence and Outcomes in the Treatment of Patients With Multiple Sclerosis.
Jing Hao, James Pitcavage, J B Jones, Carl Hoegerl, Jove Graham. J Am Osteopath Assoc 2017
13
23

Medication adherence/persistence among patients with active multiple sclerosis in Finland.
Sanni Lahdenperä, Merja Soilu-Hänninen, Hanna-Maija Kuusisto, Sari Atula, Jouni Junnila, Anders Berglund. Acta Neurol Scand 2020
12
25

Factors Affecting the Adherence to Disease-Modifying Therapy in Patients With Multiple Sclerosis.
Öznur Erbay, Öznur Usta Yeşilbalkan, Nur Yüceyar. J Neurosci Nurs 2018
12
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.